| Market Capitalization (Millions $) |
24 |
| Shares
Outstanding (Millions) |
22 |
| Employees |
11 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-8 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Nanoviricides Inc is a biopharmaceutical company that focuses on developing nanomedicines to combat viral infections. Their nanoviricides are designed to target specific viruses and prevent their replication inside the human body. Nanoviricides Inc utilizes nanotechnology in their drug development processes, allowing for precise targeting of viruses and minimizing off-target effects.
The company's nanoviricides are created by encasing a virus-binding ligand within a polymeric micelle that can attach to and neutralize the targeted virus. These nanoviricides can be administered orally or topically, providing a non-invasive and convenient treatment option for viral infections.
Nanoviricides Inc's approach offers several advantages over traditional antiviral drugs. The nanoviricides can potentially target a wide range of viruses, including those that mutate rapidly, and may be effective against emerging viral strains. Additionally, their nanotechnology-based platform allows for rapid development and production of new drugs, offering the potential for quicker responses to viral outbreaks.
The company has a strong focus on research and development, investing in preclinical and clinical studies to evaluate the safety and efficacy of their nanoviricides. They collaborate with academic institutions and government agencies to advance their technology and explore new applications. Nanoviricides Inc aims to address unmet medical needs by developing effective treatments for viral infections that have limited or no available therapies.
Company Address: 1 Controls Drive Shelton 6484 CT
Company Phone Number: 937-6137 Stock Exchange / Ticker: NYSE NNVC
|
